NovartisCancer Profile Banner
Novartis Cancer Profile
Novartis Cancer

@NovartisCancer

Followers
28K
Following
107
Media
1K
Statuses
2K

Join the conversation as we work to improve the lives of those with cancer. See our community guidelines: https://t.co/KWTwKv5451

Joined June 2016
Don't wanna be here? Send us removal request.
@NovartisCancer
Novartis Cancer
4 months
This FDA approval provides health care teams with more options to address the individual needs of patients living with advanced cancers earlier in the treatment journey. #ReimaginingMedicine.
@NovartisUS
Novartis US
4 months
Today’s regulatory milestone represents a step forward for patients, loved ones and providers who have been in need of more options to treat advanced prostate cancer earlier. #NovartisUS #ReimaginingMedicine
0
2
5
@NovartisCancer
Novartis Cancer
7 months
RT @NovartisUS: Join us at #SABCS24 to explore the stories of people touched by #breastcancer, as shared in their own words. Our Novartis e….
0
1
0
@NovartisCancer
Novartis Cancer
9 months
This FDA approval for adults with newly diagnosed chronic myeloid leukemia (#CML) is momentous for the clinical and patient communities. As the latest milestone in our 20+-year legacy in CML innovation, we are excited to bring new treatment options to patients who need them.
@NovartisUS
Novartis US
9 months
A milestone like an FDA approval requires teamwork. We are working diligently for people living with chronic myeloid leukemia (#CML). Learn more about what this FDA approval means for CML patients: @LLSusa.
1
0
3
@NovartisCancer
Novartis Cancer
9 months
Chronic myeloid leukemia (#CML) is a chronic disease that requires long-term daily therapy. Today’s FDA approval adds another choice for people living with CML. #ReimaginingMedicine.
@NovartisNews
Novartis News
9 months
Novartis announces FDA approval for adults with newly diagnosed along with previously treated Ph+ chronic myeloid leukemia (#CML) in chronic phase, offering superior efficacy, and favorable safety/tolerability profile. #NovartisNews #ReimaginingMedicine
0
1
3
@NovartisCancer
Novartis Cancer
10 months
Together with the patients, doctors and researchers who collaborated to enable today’s FDA approval of a new medicine to help prevent recurrence after early #breastcancer, we’re #reimaginingmedicine for people whose experience with this disease doesn’t end with remission. #bcsm
4
2
9
@NovartisCancer
Novartis Cancer
1 year
@NovartisUS
Novartis US
1 year
Through our “More Than Just Words” initiative, we have created an immersive virtual reality experience. Its purpose? To forge stronger bonds between healthcare providers and their Black patients. Explore this transformative tool at #ASCO2024.
1
0
2
@NovartisCancer
Novartis Cancer
1 year
1.2 to 1.5 million people are living with chronic myeloid leukemia (#CML) worldwide. This new data presented at #ASCO24 could offer hope to adults living with this difficult disease, advancing our mission to #reimaginemedicine for these patients.
@NovartisNews
Novartis News
1 year
Phase III ASC4FIRST data presented at ASCO shows superior MMR benefit with a tolerable treatment profile vs. investigator-selected SoC TKIs for adults with newly diagnosed CML #NovartisNews
0
2
4
@NovartisCancer
Novartis Cancer
1 year
Together with scientists and patients, we are striving to address unmet needs for adults with newly diagnosed #CML, unlock new possibilities for cancer patients, and deliver more equitable care. Let’s #ReimagineMedicine together. #ASCO24 #EHA24.
@NovartisNews
Novartis News
1 year
Novartis highlights pioneering innovation in chronic myeloid leukemia with data in newly diagnosed patients at ASCO and EHA. Read More: #NovartisNews #ReimaginingMedicine #ASCO24 #EHA24.
0
0
1
@NovartisCancer
Novartis Cancer
1 year
RT @NovartisUS: Today, Indiana state officials, and professional and patient groups joined us for an opening ceremony event to celebrate ou….
0
4
0
@NovartisCancer
Novartis Cancer
2 years
RT @NovartisNews: Novartis expands production with addition of its largest and most advanced radioligand therapy manufacturing facility in….
0
2
0
@NovartisCancer
Novartis Cancer
2 years
Patients at risk of recurrence from #earlybreastcancer need more options to stay cancer-free. The updated analysis from our Phase III NATALEE trial in a broad population with HR+/HER2- #EBC at #SABCS23 could help transform adjuvant care. Learn more:
2
0
2
@NovartisCancer
Novartis Cancer
2 years
RT @NovartisNews: At #SABCS23 & #ASH23, we are presenting data from over 100 trials across its breast cancer and hematology portfolios, inc….
0
2
0
@NovartisCancer
Novartis Cancer
2 years
#Movember: Your PSMA levels can determine the health of your prostate and if you need to seek additional care. Stay proactive – consult your doctor and schedule regular check-ups to stay on top of your prostate health.
0
1
3
@NovartisCancer
Novartis Cancer
2 years
Metastatic #prostatecancer is when the cancer spreads to other parts of the body. Approximately 700,000 men are currently living with this metastatic disease. At Novartis, we are making the promise of next-generation medicines a reality for people living with cancer. #Movember
0
3
1
@NovartisCancer
Novartis Cancer
2 years
Our leadership in #radioligandtherapy (RLT) is powered by our people, many of whom have deep personal connections to cancer and understand how RLT can potentially impact the lives of those touched by cancer.
0
0
3
@NovartisCancer
Novartis Cancer
2 years
With many #radioligandtherapies (RLTs) in our pipeline & clinical trials underway, we’re expanding our ability to deliver to patients today & into the future. From production to administration, we’re working to change the way patients receive their care.
0
1
3
@NovartisCancer
Novartis Cancer
2 years
Despite accounting for more than 2 million new diagnoses each year, more needs to be down to tackle the barriers to better care and patient outcomes for those living with #LungCancer. We are committed to pushing boundaries and focusing on more understanding around the condition.
@LCAM_org
LCAM Coalition
2 years
Lung cancer is a global disease. We need more research, more screening, and more treatment options to improve outcomes and increase.survival. #lungcancer #LCAM.#LungCancerAwarenessMonth
Tweet media one
0
1
2
@NovartisCancer
Novartis Cancer
2 years
We are dedicated to pushing the boundaries of #CancerCare to support patients worldwide. This #NETCancerDay, learn more about this often misdiagnosed cancer type due to the vague nature of its common symptoms that can be interpreted as other conditions.
1
0
1
@NovartisCancer
Novartis Cancer
2 years
More than 2 million people are diagnosed with #LungCancer yearly, and each one has their own unique cancer journey. At Novartis, we are committed to improve patient outcomes through innovative medicines. Learn more this #LCAM:
0
1
2
@NovartisCancer
Novartis Cancer
2 years
What is PSMA, and why does it matter? An over expression of PSMA has been linked to #prostatecancer and worse outcomes for patients. Staying proactive is key to managing disease. No matter how small your concern is each question matters. #Movember
0
0
2